Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors

NCT06472388 is registered in ClinicalTrials.gov with AC Camargo Cancer Center as lead sponsor.

NCT NCT06472388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06472388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors
Lead sponsor
AC Camargo Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
April 24, 2024
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumor carcinoid, neuroendocrine tumor grade 1, neuroendocrine tumor grade 2, neuroendocrine tumor of pancreas, neuroendocrine tumor of the lung, neuroendocrine tumors, progression